Oral vinorelbine: a practical approach to patient management
Mark Foulkes Nurse consultant in cancer care/trust lead cancer nurse, Berkshire Cancer Centre, Royal Berkshire NHS Foundation Trust, Reading, England
Carole Farrell Teaching fellow/honorary lecturer, University of Manchester, Manchester, England
Thomas Allum Macmillan patient information and support service manager, Imperial College Healthcare NHS Trust, London, England
Jane Beveridge Deputy nurse director, Weston Park Hospital, Sheffield, England
Victoria Harmer Consultant nurse in breast care, Imperial College Healthcare NHS Trust, London, England
Oral vinorelbine has been a well-established cytotoxic treatment for non-small cell lung cancer and metastatic breast cancer since 2004. This article summarises the applications of the drug, the advantages and challenges of using an oral agent in palliative oncology settings and how oral vinorelbine has been used to develop nurse-led services and chemotherapy outside traditional hospital environments. The article includes two case studies to place this treatment in a clinical context.
Cancer Nursing Practice.
Foulkes M, Farrell C, Allum T et al (2018) Oral vinorelbine: a practical approach to patient management. Cancer Nursing Practice. doi: 10.7748/cnp.2018.e1467
This article has been subject to external double-blind peer review and checked for plagiarism using automated software
Conflict of interest
Mark Foulkes has previously received honoraria for consultancy and advisory roles for Pierre Fabre Ltd
Published online: 02 May 2018
Want to read more?
Already subscribed? Log in
Unlock full access to RCNi Plus today
Save over 50% on your first 3 months
Your subscription package includes:
- Unlimited online access to all 10 RCNi Journals and their archives
- Customisable dashboard featuring 200+ topics
- RCNi Learning featuring 180+ RCN accredited learning modules
- RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests
Alternatively, you can purchase access to this article for the next seven days. Buy now